Merck & Co., Inc. has committed $30 million in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to create an updated formulation of its licensed Ebola vaccine optimized for cost-effective manufacturing and broader distribution in low- and middle-income countries. The program will fund process improvements aimed at reducing raw-material usage and enabling technology transfer to regional producers, with a target annual production capacity of 5 million doses by 2028. Regulatory submissions are expected in multiple African markets by 2027, following Phase 1 bridging studies to confirm equivalent immunogenicity and safety profiles. By expanding access and lowering per-dose production costs by an estimated 40%, Merck anticipates both enhanced epidemic preparedness and a sustainable revenue stream from government and multilateral procurement contracts.